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1. Introduction  
Allergic diseases affect millions of people around the world. Enhanced prevalence and the 
chronic characteristics of these illnesses represent an important public health problem. Most 
prevalent allergic diseases are classified as immediate-type reactions such as urticaria, 
allergic conjuctivitis, food allergy, allergic rhinitis, anaphylaxis and asthma (Sicherer & 
Leung, 2004; Fonacier et al., 2010; Sicherer, 2011). The immediate-type reaction terminology 
is applied to allergic reactions because the symptoms develop few minutes after allergen 
contact. The immune mechanisms responsible for the initiation of these reactions depend on 
the production of immunoglobulins (IgG1 and/or IgE) that activate cells such as mast cells, 
eosinophils and basophils. Once activated, these cells are responsible for release of 
inflammatory mediators, contributing to the exacerbation and maintenance of the allergic 
processes (Lampinen et al., 2004). Urticaria is characterized by pruritic, edematous and 
erythematous lesions that affect 15% to 25% of individuals during their lives. Most of the 
cases are acute but about 30% of patients present symptoms for more than six weeks and are 
considered as having chronic disease. Women are more susceptible (75%) than men and 
only 1% to 5% of the cases are related to IgE-dependent reaction while most of the cases are 
considered to be induced by physical stimuli or of idiopathic nature, including autoimmune 
urticaria (Antunez et al., 2006). Allergic urticaria depends on skin mast cell activation which 
delivers preformed mediators, mainly histamine, few minutes after allergen exposure. On 
the other hand activated mast cells also produce and deliver neo-formed mediators, i.e., 
prostaglandin D2 (PGD2) and cisleukotrienes (cisLT) that stimulate inflammatory responses 
mediated by neutrophils, basophils, eosinophils and T lymphocytes (Funk, 2001; Harizi et 
al., 2008; Kambe et al., 2010). Another allergic disease of great importance in public health is 
allergic conjunctivitis. Allergic conjuctivities prevalence in the United States was estimated 
to affects about 40 million people. Allergic conjunctivitis is marked by the presence of 
eosinophil cells in conjunctiva mucosa (Bezerra & Santos, 2010). Food allergy, another 
allergic disorder, is related to the genetic susceptibility of individuals to eggs, peanuts, 
seafood (e.g. shrimp, lobsters, crabs, squids and mussels milk and others). Oral sensitization 
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with shrimp tropomyosin induces in mice allergen-specific IgE, T cell response and systemic 
anaphylactic reactions (Capobianco et al, 2008). Food allergy has been reported in some 
cohort studies which describe variable rates of food allergy prevalence in the United States, 
Canada, the United Kindom, Singapore and the Philippines (Berin & Mayer, 2009). 
Approximately 1% of food allergic patients develop signs and symptoms characterized by 
intense diarrhea, urticaria and anaphylaxis. There are divergences about the period of 
exposition to food allergens and development of disease symptoms. Studies showed that 
allergenic food ingested during pregnancy increases the risk of higher prevalence of allergic 
response in infants (Sausenthaler et al., 2011). In contrary to the aforementioned, other 
studies suggested that earlier exposure to food allergens may promote a protective response 
to allergic conditions. Serologic diagnosis of patients with food allergies have demonstrated 
high levels of specific IgE. The pathological immune response observed in these patients 
depended on: (i) the presence of an adjuvant responsible for stimulating inflammatory 
response which is considered one necessary step to initiate lymphocyte responses, (ii) 
allergen doses which can induce classical or alternative mechanisms of allergic process in 
response to food as seen in cutaneous sensitization to food allergens and (iii) the types of 
mediators delivered which can lead to systemic allergic reactions such as anaphilaxis (Berin 
& Mayer, 2009; Sicherer & Leung, 2011). In addition, asthma, which probably may be the 
most important allergic disorder, affects about 300 million people in the world and causes 
an estimated 250,000 deaths annually. This illness is characterized by a reversible lower 
airway inflammation, airway hyperresponsivenss, mucus hypersecretion, leukocyte 
recruitment to lung tissue and airway remodeling that might cause respiratory deficits. 
Increased prevalence and difficulties in asthma control are responsible for the elevated costs 
to health systems around the world (Busse & Lemanski, 2001; Mayr et al., 2003; Bateman et 
al., 2008).  
During asthmatic crises, patients develop an intense breathing difficulty called airway 
hyperreactivity (AHR). This response occurs as a consequence of the exposure of the inhaled 
route to the environmental allergen, thereby increasing the respiratory pause. An array of 
inflammatory mediators such as histamine, cisLT, PGs, cytokines, chemokines and others 
present in the lung tissue elicit smooth muscle cell contraction, mucus production, lung 
inflammation and airway remodeling. Mucus hypersecretion and bronchiole obstructions 
are important features of asthmatic patients. These effects of the inflammatory mediators 
may worsen the respiratory functions. In the last decade studies have shown the 
involvement of some mediators in stimulating the mucus production by cells named globlet 
cells. Concomitant to lung enhanced respiratory pause and lung obstruction, recruitment of 
inflammatory leukocytes to bronchoalveolar space initiates a cellular response that might 
become a destructive response to the lung tissue architecture in a chronic phase of the 
disease. Different leukocytes participate in the inflammatory process in the lung, i.e., 
neutrophils, mononuclear cells and mainly eosinophil cells (Cowden et al., 2010). Similar 
cellular and molecular immunological mechanisms related to asthma are described in 
allergic rhinitis demonstrating a strong correlation between these two allergic disorders 
with the same etiology. Rhinitis is an upper airway allergic inflammation and is considered 
co-morbidity to asthma as several studies have suggested that upper and lower airway 
inflammations are a unique entity. The prevalence of this disease has been increasing in 
many countries and an association between asthma and allergic rhinitis has been shown. 
Although asthma and allergic rhinitis show certain particularities, both present similar 
pathophysiology with IgE-dependent allergic reactions. Another severe IgE-dependent 
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allergic reaction is the anaphylactic shock triggered by allergens such as bee venom, 
domiciliary dust, cockroaches, food, pollen, and/or medicines after mast cell sensitization 
and activation (Bateman et al., 2008). The term ‘anaphylaxis’ was used for the first time by 
Richet and Portier (1902) to describe a potentially fatal reaction that may affect different 
organs and systems and the process by which all the symptoms derived from 
pharmacologic mediators, i.e. histamine, are released by blood leukocytes as eosinophils 
and basophils. Mortality rate of anaphylaxis have been increasing around the world in the 
last decades and at least twenty people die every year in UK due to anaphylactic reactions 
representing one death in three million habitants a year. Although the majority of the cases 
of anaphylactic reactions are related to high levels of IgE and histamine, some patients do 
not present these serum biologic markers, suggesting in these cases an IgE-independent 
mechanisms (Pumphrey, 2004; Moneret-Vautrin & Mertes, 2010; Seidel et al., 2010). 
2. Immune mechanisms for the initiation of allergic reactions 
The allergen sensitization phase is related to multiple factors including gene polymorphisms 
of HLA, FcεRI-ǃ and IL-4 family, environmental factors like vaccination for prevention of 
diseases, pollutants present indoors and outdoors and viral infections. IgE is a critical 
participant in the onset of the effector phase of allergies due to its affinity to receptors 
(FcεRI) present on the surface of mast cells, basophils and/or eosinophils. The cross-linking 
between two IgE molecules and the allergen is responsible for cellular activation and 
subsequent release of preformed mediators, i.e., histamine from the cytoplasmic granules as 
well as neo-formed mediators such as eicosanoids (leukotrienes, prostaglandins and 
thromboxane) (Maddox & Schwartz, 2002). These mediators increase vascular permeability, 
induce smooth muscle contraction causing difficulty in breathing as well as the proliferation 
of fibroblasts and smooth muscle cells (Kanaoka & Boyce, 2004). The IgE production by 
allergen-specific B cells is associated with Th2 cell profile with IL-4, IL-5 and IL-13 
productions. The IL-4 and IL-13 induce in B cells the production of allegen-specific- IgE 
(Munitz et al., 2008) and IL-5 induces the production, activation and differentiation of bone 
marrow-derived eosinophil (Takatsu & Nakajima, 2008). Among the cell types mentioned 
above, mast cells are of fundamental importance in the first phase of allergic disease due to 
their wide distribution throughout the body including skin, lungs and gastrointestinal tract 
(Maurer & Metz, 2005). Recently, some scientific work showed that mast cells are able to 
migrate to the smooth muscles of the airways of asthma patients, corroborating the 
interaction between mediators released by mast cells and smooth muscle response in the 
asthmatic lung (Brightling et al., 2003).  
Another important cell population in the pathophysiology of asthma is the eosinophil. This 
cell participates in the late phase of the inflammatory response and it was initially described as 
a component of defense against intestinal parasites (Gleich et al., 1993; Weller, 1997; 
Rothenberg, 1998). However, there are several lines of evidence that contradicts this view, and 
demonstrate the eosinophils as multifunctional cells involved in the initial processes and 
propagation of various inflammatory diseases. They are also involved in the regulation of 
innate and adaptive immune responses (Rothenberger & Hogan, 2006). Eosinophils can 
respond to different stimuli as nonspecific tissue injury, viral infections, allograft, allergens, 
and tumors. Additionally, these cells release cationic proteins stored in granules as eosinophil 
peroxidase (EPO), major basic protein (MBP), eosinophil cationic protein (ECP) and eosinophil 
derived neurotoxin (EDN). Eosinophils also release a range of cytokines including the Th2 
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profile as well as chemokines RANTES, eotaxin 1 and MIP-1ǂ (Rothenberger & Hogan, 2006). 
Eosinophils participate in many pathological processes such as parasite infections, 
gastrointestinal disorders and allergic processes such as asthma. Several studies have revealed 
the presence of high levels of MBP in bronchoalveolar lavage (BAL) of asthmatic patients that 
induces cytotoxicity to various body tissues, especially the airway epithelium (Rothenberg, 
1998). Additionally, MBP increases the reactivity of airway smooth muscle to cause 
dysfunction of the muscarinic M2 vagal nerve, known to contribute to the development of 
airway hyperreactivity, a key feature of asthma (Jacoby et al., 1993). Several studies have 
demonstrated that eosinophil activation in inflammatory reactions is associated with  
increasing number of lipid bodies (LBs) (Bozza et al., 2011). The LBs are defined as 
cytoplasmatic organelles rich in lipids, surrounded by a phospholipid monolayer, posses high 
amounts of enzymes that produce eicosanoids such as PLA2, 5-LO, 15-LO, COX, LTC4 and 
PGE synthases and also cytokines, chemokines and several kinases related with signal 
transductions. However LBs are found in small quantities in non-activated cells, they are 
associated with a wild range of pathological conditions such as cancers, infectious and 
inflammatory diseases like asthma (Bozza et al., 2009). Several inflammatory mediators are 
able to induce the leukocyte LB formation as platelet activator factor (PAF) (De Assis et al., 
2003). In eosinophils other stimuli such as prostaglandin D2 (PGD2) (Mesquita-Santos et al., 
2006), IL-5 (Bozza et al., 1998), RANTES and eotaxin also induced the LB formation (Vieira-de-
Abreu et al., 2005). In addition, in the allergic inflammation, the new LBs are observed and this 
process is mediated mainly by a cross-talk between eotaxin/RANTES via chemokine receptors 
(CCR3) with MAPK, PI3K and tyrosine kinases activation and PGD2 via an unknown receptor. 
The main site of cisLT generation in eosinophils is the LBs in the pulmonary allergic 
inflammation (Bozza et al., 2009). Moreover, the regulation of allergic reactions is carried out 
by T cells called Th1 cells (Teixeira et al., 2005), which secret cytokines such as IL-2 and INF-Ǆ, 
and by the Th17 cells that produce IL-17. Both profiles can reduce the eosinophil onset in the 
lung and the bronchial hyperreactivity (Schnyder-Candrian, et al. 2006) (Figure 1). 
3. Conventional treatment of allergic diseases 
A wide variety of medicines are used to treat allergic diseases. The 2-adrenergic agonist 
therapy is widely used as first choice for addressing the crisis of asthma (O’Byrne, 2009). 
Phenoterol and salbutamol are members of this group and are largely used to reverse 
bronchoconstriction by binding directly to 2-receptors of lung smooth muscle cells and 
inducing breathing relieve due to bronchodilatation. In vitro studies showed these drugs are 
responsible for increasing the levels of cAMP described as a regulatory second messenger of 
intracellular calcium-dependent mechanisms. Calcium is one of several molecules 
responsible for the smooth muscle contraction during acute phase of asthma crises (Mahn et 
al., 2010). Of note, side effects are observed in patients under 2-agonists therapy, mainly 
cardiac frequency increases in response to activation of cardiac 1-receptors. Potent anti-
inflammatory steroid therapy is also used to control asthma manifestations. These 
medicines are indicated to block lung inflammation mediated by inflammatory leukocytes 
such as neutrophils, eosinophils, basophils and lymphocytes that contribute to exacerbation 
of inflammatory response (Jarjour et al., 2006). As consequence of inflammation, lung tissue 
might present a cell phenotype change, referred to as ‘remodeling’ which impairs the 
physiological lung function causing respiratory deficiency and death in some of asthmatic 
patients.  
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Fig. 1. Mechanism of immediate allergic reactions. Immediate allergic reactions are 
orchestrated by Th2 lymphocytes and its major cytokines (IL-4, IL-5 and IL-13) responsible 
for inducing B cell activation and IgE secretion. Mast cell sensitization depends on IgE cross-
linking and binding with FcRI, subsequent cellular activation, histamine and leukotrienes 
releases that are crucial to bronchospasm induction. Concomitantly, eosinophils migrate to 
bronchoalveolar cavity by an IL-5 (and others) dependent mechanism. Lung damage and 
airway remodeling are caused by cationic proteins delivered by eosinophils and matrix 
extracellular protein deposition.  
Steroidal anti-inflammatory drugs are able to control these pathologic responses in airways 
by inhibition of lymphocyte functions and mainly inducing apoptosis in eosinophils, which 
is considered the major component of lung tissue damage. Steroids also can induce a variety 
of side effects like endocrine alterations, cardiovascular disturbances, psychotic crises and 
cancers (Belvisi, 2004). Combinations of 2-agonists and steroids are commonly used to 
control asthma. Another class of antiasthmatic drug that was developed about 10 years ago, 
the antileukotrienes (Montelukast® and derivatives). These drugs present both 
bronchodilator and anti-inflammatory properties. cisLT are known pro-inflammatory 
mediators and they induce vascular permeability, lung smooth muscle cell 
contraction/bronchospasm and leukocyte activation and chemotaxis (Funk, 2001). Previous 
studies reported cis-LT as the major bronchoconstrictor mediators in an asthmatic lung, 
causing sustained smooth muscle contraction. The anti-leukotriene drugs block leukotriene 
receptors in lung tissue, reversing bronchospasm in asthmatic patients. Additionally, 
leukotriene modifiers like zileutron act by blocking the 5-lipooxygenase enzyme (5-LO), 
thus inhibiting the leukotriene generation. Therefore, anti-leukotriene therapies strongly 
impair airway inflammatory response and ameliorate respiratory function (Terashima, et al. 
2002; Angelova-Fischer & Tsankov, 2005). Antagonists of the enzyme phosphodiesterase, 
aminophylline and theophylline as well as muscarinic blockers also occupy space in the 
therapeutic arsenal.  
Th2 cell B cell
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3.1 Immunotherapy of asthma 
Immunotherapy with anti-IgE has also contributed to the treatment of asthma patients who 
do not have a good response to conventional therapies (Lazaar & Panettieri, 2004; Foster et 
al., 2011). Despite anti-IgE therapy, which represents a major breakthrough in the treatment 
of asthma, the high cost of this therapy remains the major obstacle. 
4. Botanical and pharmacological study with Cissampelos sympodialis 
In northeastern Brazil, diseases such as asthma, influenza, bronchitis and rheumatism are 
traditionally treated with infusions of the root bark of Cissampelos sympodialis Eichl 
(Menispemaceae), popularly known in the region as milona, abuteira or orelha de onça 
(Correa, 1984). The Menispermaceae family was described by AL Jussieu (1789). This term is 
an allusion to the morphology of the seed that looks like the fourth form of the moon. This 
species belongs to the order Ranunculales, subdivided by Diels (1910) into eight tribes, three 
subtribes, 72 genera and approximately 400 species. These species are found on all 
continents, especially in tropical and subtropical regions. In Brazil, the Menispermaceae 
family is represented by 12 genera and 106 species distributed mostly in the Amazon forest 
(Barroso, 2004).  
The genus Cissampelos belongs to the tribe Cocculeae, and subtribe Cissampelinae and 
comprises 19 species of which nine occur in Brazil (Rhodes, 1975). This genus is one of the 
few among the angiosperms that shows diversity and uniformity. The diversity can be seen 
in vegetative habitat and leaves. The uniformity is found in the sexual expression of simple 
flowers, pistils and small flowers. In the state of Paraiba the genus Cissampelos is represented 
by three species: Cissampelos ovalifolia DC, Cissampelos glaberrima St. Hill and Cissampelos 
sympodialis Eichl. These species are found in different types of habitat, soil and vegetation, 
occurring mainly in rainforests on the Atlantic coast and hills (Barbosa-Filho et al., 1997). 
The species Cissampelos sympodialis is endemic in Brazil and is found in the Northeast and 
Southeast, from Ceara to Minas Gerais states. This species often occurs in open areas as 
shrubs in sandy soil and can be distinguished mainly by the shape of the deltoid leaves 
(Barbosa-Filho et al., 1997). The roots of Cissampelos sympodialis are widely used by Indian 
tribes and in folk medicine to treat various diseases such as diarrhea, diseases of the 
genitourinary tract and especially in respiratory tract diseases such as asthma (Corrêa, 1984). 
Both alcoholic fraction of roots (AFR) and of leaves (AFL) and some of the chemical 
components (bisbenzylisoquinolinic type alkaloids) isolated from these extracts have been 
studied. These alkaloids have been shown to have paralytic effect, cytotoxic activity 
(Kupchan et al., 1965), to stimulate the central nervous system (Sur & Pradhan, 1964), to 
prevent hypersecretion of reactive products from neutrophils and macrophages (Castranova 
et al., 1991), to inhibit the inflammatory cytokine production by peripheral blood 
mononuclear cells (Onai et al. , 1995) and bronchodilator activity (Thomas et al., 1995). 
Thomas et al (1995) showed that the AFR had a relaxing effect on smooth muscle of trachea 
and increased the cyclic adenosine monophosphate (cAMP) levels from alveolar leukocytes 
in guinea pigs in a manner similar to aminophylline which antagonizes bronchial muscle 
contractions. Similarly, studies of AFL showed inhibition of histamine and ovalbumin 
(OVA)-induced bronchospasm in guinea pigs (Thomas et al., 1997a), synthesis of 
phosphodiesterase (PDE) IV and V in the lungs of mice and induced increased levels of 
cAMP in guinea pig trachea muscle cells (Thomas et al. 1997b). Also AFL had an 
antidepressant effect probably associated with the phosphodiesterases inhibition in rat brain 
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(Almeida et al., 1998), inhibited human neutrophils degranulation (Thomas et al., 1999) and 
induced contraction of vascular smooth muscle (Freitas et al., 2000). 
5. Phytochemical study of Cissampelos sympodialis  
Chemical studies of Cissampelos sympodialis led to the isolation of different alkaloids (Barbosa-
Filho et al., 1997) such as bisbenzylisoquinolinic (warifteine,methilwarifteine, roraimine and 
simpodialine); morfinic (milonin); aporfinic (laurifolin) and oxoaporfinic (liriodenine) which 
have allowed for a more accurate immunopharmacological studies (Freitas et al., 1996, De Lira 
et al., 2002) (Table 1). Analysis of quality control of Cissampelos sympodialis extracts by 
thermogravimetry test showed that both AFL and AFR present alkaloids as major compounds 
and also both extracts showed the same kinetic behavior of bisbenzylisoquinolinic alkaloids 
(Aragão et al., 2002). Among these alkaloids warifteine showed spasmolytic activity by 
modifying various regulatory processes involving intracellular calcium channels and cAMP 
levels, which are essential for muscle contraction (Somlyo & Somlyo, 1994; Freitas et al., 1996). 
Therefore the purpose of our scientific study has been to develop a herbal medicine from the 
leaf extract of Cissampelos sympodialis to treat asthma as an alternative therapy. 
6. Current stage of knowledge of Cissampelos sympodialis 
6.1 Immunological study of Cissampelos sympodialis 
Since the relaxant effect of Cissampelos sympodialis extracts (roots and leaves) on bronchial 
smooth muscle cells (Thomas et al. 1995), inhibition of phosphodiesterases (PDE) IV and V 
in the lung with increased levels of cAMP in muscle cells of the trachea (Thomas et al. 
1997b), biological effects that corroborate with the anti-asthmatic activity of the plant were 
demonstrated, we began the immunological studies. Our research group, with laboratory 
complex located in the Laboratory of Pharmaceutical Technology (LTF), Federal University 
of Paraíba (UFPB), and in collaboration with Federal University of Rio de Janeiro and the 
Oswaldo Cruz Foundation/Rio, Brazil, has systematically studied the immunomodulatory 
effect of Cissampelos sympodialis since 1997. In vivo and in vitro tests have been conducted to 
understand the mechanisms of action of AFL as well as the isolated alkaloid warifteine in 
experimental models of allergy and inflammation. 
6.2 Toxicological study of Cissampelos sympodialis 
Several parameters can be analyzed to demonstrate the toxic potential of a plant (extracts or 
compounds) such as loss of weight, death, anorexia, and change of behavior. Therefore 
toxicological studies showed that the use of AFL in acute treatment was considered nontoxic 
with no deaths among rats after administration at dose of 5 g/kg orally (po) or of 2 g/kg 
intraperitoneally (ip) (Diniz et al., 2004). However AFL chronic treatment caused an 
anorexic effect in female rats and behavioral changes (Almeida et al., 2005).  
The alkaloids warifteine and milonine isolated from C. sympodialis showed cytotoxicity in 
fibroblast cell line (V79) derived from hamster and in hepatocytes of Wistar rats (Melo et al., 
2003). Given the mixed results of acute and chronic treatments in rats, our research group 
began studying the effect of chronic oral treatment (more than 15 days) with AFL into 
inbred BALB/c mice. We observed that this treatment induced weight gain throughout the 
treatment, suggesting lack of toxicity in these experimental animals (Bezerra-Santos et al., 
2004). 
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Structure Compound name References 
Warifteine Barbosa et al., 1997 
Methilwarifteine Barbosa et al., 1997 
Milonine Barbosa et al., 1997 
Laurifoline Alencar, 1994 
Roraimine De Lira et al., 2002 
N
H
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MeO
OH H
H
Me
H
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OH
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OMe
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+
1
3
4
4a
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12'
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14'
1'
3'
4'5' 4a'
6'
7'
8'
8a'
8a


Simpodialine -N-oxide Alencar, 1994 
Liriodenine De Lira et al., 2001 
Table 1. Alkaloids of Cissampelos sympodialis Eichl. 
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6.3 Anti-inflammatory activity of Cissampelos sympodialis 
The inflammatory process is a complex program of intracellular signal transduction and 
transcription events driven by multiple pro-inflammatory mediators and cytokines 
(Sherwood & Toliver-Kinsky, 2004). The acute inflammation is characterized by exudation 
of protein-rich fluid, edema, vasodilation and cell migration, primarily of neutrophils, into 
the site of injury (Sherwood & Toliver-Kinsky, 2004). Investigations on the anti-
inflammatory activity of AFL were performed in experimental models of acute 
inflammation using phlogistic agents in Swiss mice or rats. Prophylactic treatments (before 
the phlogistic administration) demonstrated an AFL inhibitory effect on the ear edema 
formation induced by either TPA (12-O-tetradecanoyl phorbol-13-acetate) or capsaicin in 
Swiss mice (Batista-Lima et al., 2001). The experimental model of edema induced by TPA 
involves the activation of phospholipase A2 and production of prostaglandins and 
leukotrienes while the edema induced by capsaicin involves the release of substance P, 
histamine and eicosanoids such as serotonin and prostaglandins. These mediators are 
produced and released mainly by inflammatory cells such as mast cells, basophils, 
eosinophils and macrophages (Funk, 2001). Based on the anti-inflammatory effect of AFL, 
we inferred that the plant acts on the inflammatory cells by modulating the production of 
mediators. Corroborating this hypothesis was the observation that prophylactic treatment of 
experimental animals (rats) with AFL also showed inhibition of neutrophil migration into 
the intraperitoneal cavity induced by carrageenan (Batista-Lima et al., 2001). The migration 
of neutrophils into the peritoneal cavity of rats induced by carrageenan is dependent on the 
release of eicosanoids and chemotactic agents such as leukotriene B4 and/or IL-8, 
respectively, produced by mast cells and/or resident macrophages (Lefebvre et al., 2010, 
Nakagome & Nagata, 2011). Taken together the results support the hypothesis that AFL 
treatment is modulating cytokines as well as antiinflammatory mediator effects. 
7. Immunomodulatory activity of Cissampelos sympodialis 
7.1 Effect of Cissampelos sympodialis on IL-10 and NO production 
Although eicosanoids and chemotactic agents produced by inflammatory cells are 
responsible for triggering the inflammatory process, these cells are also responsible for 
producing cytokines which control inflammation. IL-10 produced by mononuclear cells has 
been described as a potent regulatory molecule in the inflammatory process (Moore et al., 
2001). Surprisingly, in vitro studies showed, for the first time, that the inhibitory effect of 
AFL on the proliferative response of BALB/c mice spleen cells stimulated with the mitogen 
concanavalin A was associated with the production of IL-4 and IL-10 by these cells 
(Piuvezam et al., 1999). Macrophages are cells that produce IL-10 and from this perspective, 
we investigated the effect of AFL on murine resident and elicited (sodium thioglycollate) 
macrophages. The experimental model used for this purpose was the infection of 
macrophages with trypomastigote form of Trypanosoma cruzi. The AFL treatment induced an 
increase in the release of trypomastigote forms by the cells with increase in IL-10 
production. This phenomenon was shown in both types of macrophages (resident or 
elicited). The AFL was also able to increase the production of IL-10 even in the absence of 
the parasite. In addition, AFL inhibited the NO synthesis induced by interferon-gamma 
(IFN-) and lipopolysaccharide (Ding, et al., 1988; Alexandre-Moreira et al., 2003). 
Therefore these results confirm the effect of AFL in modulating the microbicidal activity of 
macrophages by increasing the IL-10 production as well as inhibition of NO synthesis. 
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7.2 Effect of Cissampelos sympodialis on the immunoglobulin production 
B cells are responsible for the production of immunoglobulins (Ig) after antigen recognition 
and activation (Snapper & Paul, 1987; Wong & Koh, 2000). Asthma reaction is an immediate-
type reaction mediated mainly by IgE (Busse & Lemanski, 2001; Mayr, et al., 2003). The 
release of mediators associated with the inflammatory cells to the reaction site induces the 
clinical symptoms of asthma (Maddox & Schwartz, 2002) such as bronchocontraction, 
mucus production and the strangling sensation (Funk, 2001). Based on the asthma 
symptoms and the fact that Brazilian folk medicine has systematically used Cissampelos 
sympodialis to prevent asthma symptoms, several studies have been conducted using the 
experimental model of asthma to demonstrate the AFL effect. The strain of inbred BALB/c 
mice is hypersensitive to ovalbumin (OVA) with the production of OVA-specific IgE, 
pulmonary hyperactivity and mucus production after sensitization and challenge with 
OVA. The chronic oral treatment (15 days before OVA sensitization) with AFL inhibited the  
total OVA-specific IgE production and increased the production of IFN-Ǆ by spleen cells of 
these mice (Bezerra-Santos et al., 2004). Alexandre-Moreira and co-workers (2003) 
demonstrated that AFL inhibited activated B cell function through an increase in 
intracellular cAMP levels. Several studies have identified cAMP as an antagonist of B cell 
proliferation induced by mitogens (Cohen & Rothstein, 1989). Also it was demonstrated that 
cAMP is a second messenger that plays an important role in the regulation of B cell 
apoptosis (Myklebust et al., 1999). In general, an increase in cAMP levels is associated with 
anti-inflammatory and immunosuppressive effects (Cohen & Rothstein, 1989; Wong & Koh, 
2000; Torgersen et al., 2002). Finally, the finding that AFL inhibited immunoglobulin 
secretion suggests a therapeutic use for the Cissampelos sympodialis extract in conditions 
associated with up regulation of B cell function and enhanced immunoglobulin secretion 
such as allergic diseases as well as autoimmune disease. 
7.3 Activity of Cissampelos sympodialis in anaphylactic shock reaction 
Anaphylaxis is a severe allergic reaction and is often fatal. It is mediated by IgE antibodies, 
mast cells and their mediators such as histamine. Medicines, insect bites and certain foods 
can trigger anaphylactic shock in genetically predisposed individuals (Teo et al., 2009; 
Dybendal et al., 2003). To have a better understanding of the effect of AFL treatment in 
allergic reactions, we evaluated the therapeutic potential of the acute treatment (five days 
before sensitization) in experimental model of anaphylactic shock using ovalbumin (OVA) 
challenge. The results demonstrated that AFL treatment was able to inhibit up to 70% death 
of OVA-sensitized mice after 1 hour of the OVA challenge. However, the same treatment 
was not able to inhibit the anaphylactic shock induced by compound 48/80. These data 
show that the effect of the extract is dependent on mechanisms involving IgE production 
(Bezerra-Santos et al., 2005). 
7.4 Eosinophil lipid body inhibition by Cissampelos sympodialis 
LBs are specialized organelles in the synthesis and storage of arachidonic acid derivatives 
such as prostaglandins and leukotrienes, and are present in the cytoplasm of various 
leukocytes and activated eosinophils (Bozza & Viola, 2010). A single treatment with AFL 
inhibited the formation of lipid bodies in eosinophils from mice sensitized and challenged 
with OVA. These results suggest that the extract is capable of modulating the synthesis of 
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inflammatory mediators important in the chemotaxis of inflammatory cells to the lungs 
during asthma attacks, as well as contraction mediators that cause bronchospasm. 
8. Warifteine, a bisbenzylisoquinoline alkaloid from Cissampelos sympodialis 
Warifteine is a major bisbenzylisoquinolinic alkaloid found in AFR as well as AFL. The 
isolated compound is an amorphous yellow crystal and the chemical name is (R)-
2,8,13,13a,14,15,16,25-Octahydro- 18,30- dimethoxy-14 -methyl -4,6:9,12:21,24 -trietheno-3H 
pyrido (3',2':14,15) (1,11) dioxacycloeicosino (2,3,4- ij) isoquinoline-5,19-diol with molecular 
weight of 592.68084 g/mol. Warifteine is insoluble in polar solvents but in acidic conditions 
becomes a water-soluble salt, allowing its in vivo and in vitro analysis without addition of 
other toxic solvents. Warifteine becomes an important compound marker for the extract 
standardization of the plant as well as a candidate for a phytomedicine (Cerqueira-Lima et 
al., 2010). 
8.1 Warifteine inhibits the histamine release 
Allergic reactions trigger organic changes according to body region affected as atopic 
dermatitis (skin), hay fever or rhinitis (upper respiratory tract), asthma (lower respiratory 
tract), food allergy (digestive tract), anaphylactic shock (systemic reaction) (Cavalher-
Machado et al., 2004; Sicherer & Leung, 2011). All of these conditions are consequence of 
sensitized mast cell degranulation which releases several mediators (histamine, CisLT or 
prostaglandins) that cause smooth muscle contraction. Histamine is also of fundamental 
importance in triggering the allergic symptoms such as swelling (Baroody & Naclerio, 2000), 
itching (Davidson & Giesler, 2010), bronchospasm (Larsen, 2001) and anaphylactic shock 
(Valent et al., 2011). Warifteine effect in mast cell degranulation was then investigated. 
Initial findings came from in vitro assays which showed that warifteine was able to relax 
smooth muscle independently of endothelium, i.e., it did not only control the tone muscle in 
vessels but also relaxed the bronchioles muscles (Freitas et al., 1996). Warifteine then 
becomes an important tool in attempting to prevent or reverse the respiratory distress 
occurring during asthmatic attacks (Priel et al., 1994). To evaluate the alkaloid activity on 
mast cell degranulation we used several experimental models. At first OVA-sensitized mice 
were orally treated with warifteine then OVA-challenged in their paws. An inhibition of 
edema formation was observed (Costa et al., 2008). Passively IgE anti-DNP/BSA-sensitized-
paw of rats were treated with warifteine and challenged with DNP/BSA and the results 
demonstrated that the treatment inhibited the hyperalgesia reaction, showing modulation 
among mast cells, vessels and nerves. Mimicking a local allergic reaction like a bee sting, the 
intra dermal administration of the secretagogue compound 48/80 in mice induces mast cell 
degranulation with histamine release and consequently induction of scratching behavior 
(Inagaki et al., 2002). We demonstrated that warifteine treatment inhibited the itching, 
indicating a direct effect in mast cell degranulation (Costa et al., 2008). Mast cells from 
dorsal subcutaneous tissue and peritonea from OVA sensitized rats were cultured with 
warifteine and after OVA challenge the histamine release was measured. The warifteine 
inhibited significantly the histamine release from tissue and peritoneal mast cells in a similar 
manner to sodium cromoglycate (CGS) (Costa et al., 2008). These data indicate that 
warifteine is inhibiting the mast cell degranulation and histamine release. 
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8.2 Warifteine inhibits the B cell functions 
Several models have been employed for analyzing B cell response in vitro. Anti-IgM 
antibodies (Ab) have been used as a model for studying signals induced by binding to B cell 
surface Ig (Mond et al., 1995) and also T-independent type 2 antigens (TI-2), which activate 
B cells through a broad cross-linking of their Toll-like receptors (TLR) (Vos et al., 2000; Peng, 
2005). Warifteine was then analyzed on B cells. It was observed that warifteine inhibited 
both B cell proliferation and Ig secretion induced by TLR ligands (LPS, Pam3Cys and CpG 
oligodeoxynucleotide) or anti-IgM Ab. These effects were not due to a toxicity since 
warifteine neither induced alteration in propidium iodide labeling of fresh spleen B cells or 
modified XTT metabolization by the B cell line A20. Also the inhibitory effect of B cell 
activated with TLR activators or anti-IgM Ab did not modify the total protein 
phosphorylation pattern, however it attenuated the rise in intracellular calcium levels, the 
phosphorylation of mitogen-activated protein kinase (MAPK) ERK and the intracellular 
levels of transcription factor NFκB. Warifteine also increased the cAMP level. In vivo study 
showed that pre-treatment with warifteine inhibited the anti-TNP-ficoll titles in BALB/c 
mice immunized with TI-2 antigen TNP-ficoll (Rocha et al., 2010). Taken together, the data 
showed that the alkaloid present in the AFL of Cissampelos sympodialis is one of the 
compounds responsible for the B cell modulatory effect. 
8.3 Warifteine inhibits the eosinophil activity 
A characteristic feature of asthma is a chronic inflammation with degeneration of bronchial 
epithelium in an eosinophil-dependent mechanism. Eosinophils release cationic proteins, 
chemotactic agents (eotaxin) and eicosanoids (cis-LT) (Ono et al., 2008). The treatments with 
warifteine or AFL inhibited eosinophil migration into the pleural and bronchoalveolar 
cavities of OVA sensitized BALB/c mice. Both warifteine and AFL were also capable of 
inhibiting the secretion of cis-LT and eotaxin, suggesting a role for AFL and its alkaloid in 
controlling the inflammatory process, thus corroborating the belief of an alternative 
treatment for diseases associated with eosinophil activity. 
9. Cellular and molecular therapeutic targets for Cissampelos sympodialis 
Studies performed for 15 years have contributed to the unraveling of part of the 
immunopharmacological mechanisms involved in Cissampelos sympodialis and warifteine 
effects. Figure 2 presents different cellular and molecular therapeutic targets for the plant 
extract and its alkaloid. 
10. Relevance of the proposal for new herbal medicine 
Some allergic diseases of major public health concerns are classified as immediate-type 
hypersensitivity, atopic dermatitis, food allergy, rhinitis, allergic asthma and anaphylactic 
shock. The incidence of allergic asthma is increasing at an alarming rate in developing 
countries like Brazil where around 35% of the population experience allergic diseases 
including asthma (Brazilian Association of Allergy and Immunopathology. 2007). Asthma is 
considered a public health problem. A significant variety of medicines such as bronchodilators 
and potent anti-inflammatory drugs that mitigate the crisis is used to treat asthma but with 
undesirable side effects. Our research group, with multidisciplinary profile, has been studying 
in a systematic way, the plant extracts of Cissampelos sympodialis and its components on  
www.intechopen.com
Cissampelos sympodialis (Menispermaceae): 
A Novel Phytotherapic Weapon Against Allergic Diseases? 
 
489 
 
 
Fig. 2. Therapeutic targets for Cissampelos sympodialis. In vitro and in vivo studies showed that 
C. sympodialis induces IL-10 production by macrophages and IFN- production by 
splenocytes from OVA-sensitized mice. Oral treatment with AFL and warifteine inhibited 
OVA-specific IgE serum titer and mononuclear cell proliferation. Also both AFL as well as 
warifteine inhibited neutrophil and eosinophil migration and activation (PDE activity, 
leukotriene generation and lipid body formation) to the pleura and bronchoalveolar cavity 
induced by flogistic stimulus or allergens. Additionally, warifteine inhibited histamine 
delivery by mast cell and attenuated hyperalgesic reaction in rats.  
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experimental models of inflammation and allergy. The accumulated data showed that the 
extracts and its major alkaloid, warifteine, present potent anti-inflammatory effects, prolong 
the time of onset of anaphylactic shock reaction with reduction in allergen-specific IgE 
production, inhibit the inflammatory cell recruitment to the airways, relax airway smooth 
muscle in guinea pigs as well as modulate the production and release of inflammatory 
mediators such as histamine and cytokines. In addition, the great similarity in chemical 
structure among the alkaloids warifteine and milonine of Cissampelos sympodialis with drugs 
traditionally used in therapy: tubocurarine (potent muscle relaxant) and codeine (analgesic, 
antitussive and narcotic) respectively, (Figure 3), justified the popular use of the plant to 
treat respiratory diseases and the effort to produce an herbal medicine from this Brazilian 
plant. 
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Fig. 3. Warifteine and tubocurarine are alkaloids that have the same chemical skeleton and 
belong to the class of bisbenzylisoquinoline. Milonine and codeine are alkaloids that have 
the same chemical skeleton and belong to the class of Morphinans. 
11. Why Cissampelos sympodialis has potential as a herbal medicine? 
1. Cissampelos sympodialis is used in folk medicine and by Indian tribes, in Northeast 
Brazil, for the treatment of disorders of airways such as asthma and rhinitis. 
2. The preclinical data showed low or no toxicity on oral administration of the extract 
depending on the animal model used. 
3. Studies of mechanisms of action of the extract have demonstrated efficacy in reduction 
of pathophysiological characteristics of allergic diseases associated with chronic 
inflammations such as asthma. 
4. The leaf extract of the plant presents milonine, which is a morphinic alkaloid with a 
codeine-like chemical structure. Codeine is a classic drug with antitussive and analgesic 
properties. 
5. Warifteine, one of the major alkaloids of the plant, presented similar effect of the extract 
in reducing asthma pathological profile. 
6. Chemical structure of warifteine is similar to the tubocurarine chemical structure. 
Tubocurarine is a classic drug with muscle relaxant property. 
7. Warifteine can be used as a molecular marker for the standardization of herbal 
medicine. 
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